Back to Agenda
Session 5: De-Centralization of Clinical Trials – Different Stakeholder Perspectives
Session Chair(s)
Elke Stahl, PHD
Senior Expert, Clinical Trials Department, Federal Institute For Drugs and Medical Devices (BfArM), Germany
Getting insight in different stakeholders’ perspectives on decentralised clinical trials. Their experiences with decentralised elements gained in clinical (hybrid) trials - the advantages and challenges.
Speaker(s)
Mireille Muller, DRSC, PHD, MSC
Regulatory Policy & Intelligence Director, Novartis Pharma AG, Switzerland
Sponsors Perspective
Ghislaine Van Thiel, PHD, MSC
Ass. Professor Medical ethics, University Medical Center Utrecht, Netherlands
Ethical Side of Digitalisation of Clinical Trials
Greet Musch, PHD
strategic adviser , FAMHP, Belgium
Regulators Perspective on Expectations for the Future?
Jan Geissler, MBA
Managing Director, Patvocates, Germany
Patient Organisations – Advantages and Disadvantages of Digitalisation
Ruediger Pankow, DRSC
Clinical Trial Regulatory Consultant | CTIS SME, Independent Consultant, Germany
Panel discussion with Q&A, with participation of:
Have an account?